News Desk: On Friday, Bharat Biotech announced the start of Phase 1 human clinical trial of Covaxin.
Bharat Biotech notified on twitter, “India’s First Indigenous COVID 19 Vaccine, COVAXIN, initiated Phase-1 clinical trials across the country on 15th July 2020.”
The human trial of Covaxin, India’s first vaccine candidate against the novel coronavirus infection, started last week. All India Institute of Medical Sciences in Patna and Post-Graduate Institute of Medical Sciences in Rohtak have begun the clinical trial of the COVID-19 vaccine candidate. The vaccine has been developed by the Hyderabad-based pharmaceutical company Bharat Biotech in collaboration with the National Institute of Virology (NIV) and the Indian Council of Medical Research (ICMR). The Drug Controller General of India (DCGI) earlier approved the biotech company to initiate phase I and II human clinical trials.
The SARS-CoV-2 strain was isolated in NIV, Pune, and transferred to Bharat Biotech.
Covaxin got the nod for human trials by the Drug Controller General of India on June 29. “The Drug Controller General of India – CDSCO, Ministry of Health & Family Welfare granted permission to initiate Phase I & II Human clinical trials after the company submitted results generated from preclinical studies, demonstrating safety and immune response,” Bharat Biotech had said earlier.
Image Source: Internet
